| Fecha | Trimestre | Sesión | BPA (est → real) | Ingresos (est → reales) |
|---|---|---|---|---|
| 26 oct 2026Próximo | Q3 2026 | Antes de apertura | 1,32 | 712 M |
2 sept 2026
1 sept 2026
Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Revvity's (RVTY) strong portfolio faces slowing growth and rising competition, raising questions abo
RBC Capital analyst Dan Leonard initiates coverage on Revvity (NYSE:RVTY) with a Sector Perform rating and announces Price Target of $135.
24 ago 2026
Investors need to pay close attention to RVTY stock based on the movements in the options market lately.
Revvity has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.
13 ago 2026
RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.
Revvity’s second quarter demonstrated year-over-year growth in both revenue and non-GAAP earnings, yet the market responded negatively, likely reflecting concerns about underlying segment dynamics and external factors. Management highlighted continued strength in its Diagnostics franchise, supported by robust organic growth and consistent performance in reproductive health and immunodiagnostics outside China. CEO Prahlad Singh pointed to "tangible signs of a more constructive spending environmen
11 ago 2026
Diagnostics surged 11% organically as AI-driven demand accelerated.
WALTHAM, Mass., August 11, 2026--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:
10 ago 2026
WALTHAM, Mass., August 10, 2026--Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows.
9 ago 2026
Revvity (NYSE:RVTY) reported second-quarter results above its expectations and raised its full-year outlook, citing continued strength in diagnostics, improving demand from pharmaceutical and biotechnology customers, and growing orders tied to artificial intelligence-enabled drug discovery workflows
6 ago 2026
Revvity, Inc. reported past second-quarter 2026 results with sales of US$729.69 million, net income of US$51.82 million and diluted EPS from continuing operations of US$0.48, while also reaffirming a regular US$0.07 per-share quarterly dividend and issuing full-year 2026 revenue guidance of US$2.83 billion to US$2.86 billion. Management attributed the earnings beat and raised outlook to improving pharma and biotech spending, strong Diagnostics growth, especially in reproductive health and...
5 ago 2026
Evercore ISI Group analyst Vijay Kumar maintains Revvity (NYSE:RVTY) with a Outperform and raises the price target from $125 to $126.
Moby summary of Revvity, Inc.'s Q2 2026 earnings call
4 ago 2026
Revvity beats Q2 earnings and sales estimates as Diagnostics growth, wider margins and strong cash flow support a higher 2026 outlook.
Revvity Inc (RVTY) beats expectations with 3% organic growth, raises full-year outlook on robust diagnostics performance and AI-driven demand.
2026-08-04. The following slide deck was published by Revvity, Inc.
Revvity, Inc. (RVTY) Q2 2026 Earnings Call August 4, 2026 7:30 AM EDTCompany ParticipantsStephen Willoughby - Senior VP of Investor Relations & Head of...
Revvity (RVTY) Q2 adjusted EPS beats at $1.41, revenue in line; pro forma FY26 revenue guidance below consensus, stock premarket -0.2%.
Revvity, Inc. (NYSE:RVTY) reported second-quarter 2026 results that exceeded Wall Street expectations, prompting the health sciences company to raise its guidance for the full year.
